Pronota signed an agreement allowing its MASStermind® platform for protein biomarker discovery and its MASSterclass™ biomarker verification platform to be used by Molecuence. The company will leverage the technologies to discover and validate protein biomarkers in stroke.
Pronota develops protein biomarker diagnostics using a platform that mines for low-abundance protein biomarkers in blood and other tissues. MASSterclass™ verifies biomarkers identified by MASStermind® without the use of antibody-based assays, according to the company.
Promota's pipeline consists of four programs focused on diagnostic blood tests for cardiorenal disease, pre-eclampsia, sepsis, and ovarian cancer. Founded in late 2004, Pronota announced the raising of a series B financing round of €7.9 million (about $10.8 million) last year.
Moleculence, a wholly owned subsidiary of Mitsubishi Chemical, focuses on R&D of advanced biomarkers that can enable diagnosis and prediction of cardiovascular and metabolic diseases. Molecuence works with researchers at Kyushu University Faculty of Medicine and Hisayama Research Institute for Lifestyle Diseases.